ResApp (ASX:RAP) share price adds 4% on COVID-19 study rebate

The company's shares are continuing on yesterday's gains…

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The ResApp Health Ltd (ASX: RAP) share price is on the move again today following yesterday's meteoric rise. The digital health company provided another positive release to the ASX today.

At the time of writing, ResApp shares are fetching for 9.3 cents apiece, up 4.49%. It's worth noting that during early morning trade, its shares reached an intraday high of 10.2 cents.

Two scientists in a Rhythm Biosciences lab cheer while looking at results on a computer.

Image source: Getty Images

ResApp secures rebate on COVID-19 study

Investors are pushing ResApp shares higher after the company secured a cashback for its COVID-19 research program.

According to the release, ResApp advised it has received approval from AusIndustry for its application for an Advanced and Overseas Finding. In particular, this is in relation to the expenditure associated with its COVID-19 clinical studies.

The finding covers the financial years between 2021 to 2023, meaning that ResApp will be eligible for a cash rebate. This refers to the company's COVID-19 overseas research and development expenditure, thus receiving a 43.5% cashback from the Australian government.

As such, ResApp estimates that it will collect a rebate of around $820,000 for the financial year that ended 30 June 2021.

In the United States, the company is currently recruiting participants for its upcoming pilot study. The aim is to collect data to train an algorithm in identifying COVID-19 through cough sounds recorded on a smartphone.

The same participants will also be used in a second study to collect further cough sounds and data on disease progression. ResApp hopes to develop algorithms to remotely monitor patients with COVID-19.

ResApp CEO and managing director, Dr Tony Keating commented:

Our COVID-19 research program is looking at developing algorithms for screening for COVID-19 as well as helping healthcare systems better manage patients with COVID-19, including those with long COVID. This finding, recognising the need to collect COVID-19 cough samples internationally, provides us with a high degree of certainty in planning our programs.

We are very grateful to the Federal Government for their commitment to supporting research and development by Australian companies.

ResApp share price summary

Until recently, ResApp shares were trading at multi-year lows, before shooting up in September. The past month alone has netted investors a return of more than 115%, however year-to-date, is up marginally at 14%.

ResApp commands a market capitalisation of about $83.3 million and has 859 million shares on its books.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News

A group of happy young people watching sport on a laptop celebrate.
Share Gainers

Here are the top 10 ASX 200 shares today

It was an exceptional session for investors today.

Read more »

Smiling young parents with their daughter dream of success.
Broker Notes

Why Life360 shares could be dirt cheap and set to rise 90%

Bell Potter has good things to say about this tech stock.

Read more »

a surprised investor reading about an asx share price in a newspaper
Broker Notes

Top brokers name 3 ASX shares to buy today

Here's what brokers are recommending as buys this week.

Read more »

ASX board.
Share Market News

The ASX just hit a rare milestone. Here's what it means for your money

ASX trading activity surges as futures volumes hit record highs.

Read more »

A woman looks nervous and uncertain holding a hand to her chin while looking at a paper cut out of a plane that she's holding in her other hand.
Travel Shares

Qantas stock is down 17.7% in a month. Time to buy?

Qantas is back to April prices.

Read more »

A young man clasps his hand to his head with a pained expression on his face and a laptop in front of him.
Share Fallers

Why Amplitude Energy, Atlas Arteria, Computershare, and Woodside shares are falling today

These shares are falling on hump day. But why?

Read more »

A business person directs a pointed finger upwards on a rising arrow on a bar graph.
Broker Notes

Why this buy-rated ASX mining share is tipped to surge 112%

A leading broker expects this ASX mining share to more than double investors’ money in a year.

Read more »

Excited couple celebrating success while looking at smartphone.
Share Gainers

Why 4DMedical, Brazilian Rare Earths, Clarity, and Tuas shares are racing higher today

These shares are having a better day than most on hump day.

Read more »